|
N.A. Karoli, A.P. Rebrov
Beta-blockers in patients with chronic obstructive pulmonary disease: for whom, when, how?
|
№5 / 2020
|
|
I.V. Leshchenko (1, 2), V.E. Evdokimov (1)
The place of nebulizer therapy in clinical practice
|
№5 / 2020
|
|
A.A. Vizel (1), I.Yu. Vizel (1, 2), I.N. Salakhova (1), A.R. Vafina (1)
Adherence in bronchial asthma and chronic obstructive pulmonary disease: from a problem to a solution
|
№5 / 2019
|
|
L.V. Vasilyeva, E.F. Evstratova, V.A. Nikitin, M.N. Latysheva
Pathogenetic mechanisms for the treatment of the lumbar pain syndrome caused by osteoporosis of mixed genesis in patients with chronic obstructive pulmonary disease
|
№5 / 2019
|
|
A.I. Sinopalnikov
Antibiotics and community-acquired low respiratory tract infections. Who for? What preparation?
|
№5 / 2019
|
|
Yu.G. Belotserkovskaya, A.I. Sinopalnikov, A.G. Romanovskikh, I.P. Smirnov
The concept of controlling chronic obstructive pulmonary disease
|
№5 / 2019
|
|
A.V. Emelyanov, E.V. Leshenkova, G.R. Sergeeva
Inhaled glucocorticosteroids in the treatment of chronic obstructive pulmonary disease: the debate continues
|
№5 / 2019
|
|
A.A. Vizel, I.Yu. Vizel, I.N. Salakhova, A.R. Vafina
TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM ANALYSIS TO PRACTICE
|
№14 / 2017
|
|
I.N. Trofimenko, B.A. Chernyak
CLINICAL AND FUNCTIONAL FEATURES AND BRONCHOPROTECTIVE EFFECT OF M-CHOLINOLITHICS IN PATIENTS WITH COPD WITH BRONCHIAL HYPERREACTIVITY
|
№14 / 2017
|
|
A.F. Verbovoy (1), I.A. Tsanava (1), N.I. Verbovaya (1), R.A. Galkin (1), I.V. Madyanov (2)
POLYMORBIDITY AND MODERN MEDICINE
|
№16 / 2017
|
|
V.N. Shishkova
PROBLEMS OF COMORBID PATIENT AND POLYPRAGMASY IN NEUROLOGY
|
№9 / 2017
|
|
I.N. Trofimenko, B.A. Chernyak
CLINICAL CHARACTERISTICS OF EOSINOPHILIC PHENOTYPE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
№4 / 2017
|
Русский
